Last updated: April 26, 2026
What form of “mometinib dihydrochloride” is the market actually sourcing?
“Mometinib dihydrochloride” is typically purchased as a small-molecule kinase inhibitor drug substance (API) in dihydrochloride salt form. The buyer-facing product descriptions on commercial catalogs usually map to one of these supply positions:
- API manufacturer / API supplier (direct): produces the active pharmaceutical ingredient and sells under GMP or to wholesalers/CMOs.
- Commercial chemical supplier (trader / distributor): sources API via distributor networks or from API manufacturers and sells with non-clinical paperwork unless specified as GMP.
- CMO-managed synthesis: buyer commissions synthesis and salt formation (dihydrochloride), usually through an integrated development and manufacturing package.
Critical procurement detail: If the intent is clinical or commercial manufacturing, “supplier” must be an API supplier with GMP batch capability for the specific salt form, not just a catalog chemical source.
Which supplier types should pharmaceutical buyers use for mometinib dihydrochloride?
Because “mometinib dihydrochloride” is a targeted oncology API, the procurement path is usually segmented:
- GMP API manufacturers
- Provide CoA, GMP documentation, and traceability.
- GMP contract manufacturing organizations (CMOs) with API capability
- Provide a development-to-commercial route, including salt screening and dihydrochloride formation.
- Distributors only when non-GMP material is acceptable
- Fast access, but documentation and regulatory readiness vary.
How to screen suppliers for the correct salt form and regulatory readiness
When a buyer searches “mometinib dihydrochloride,” the highest-risk failure mode is incorrect polymorph/salt form or non-GMP supply. The supplier vetting checklist that matters most in practice:
- Salt identity
- Written confirmation it is the dihydrochloride salt.
- Reference to characterization methods (typ. XRPD, DSC, titration, HPLC method).
- Specification package
- Establishes acceptance criteria for assay, related substances, residual solvents, and water content.
- Manufacturing control
- Batch manufacturing record support (at least via CoA + GMP statement depending on stage).
- Stability and form control
- Data showing stability in the proposed storage/packaging conditions for the salt form.
Supplier lists: what can be stated with evidence from public sources
This request cannot be completed as stated because it requires a specific, sourced supplier roster (named companies and which they supply) for mometinib dihydrochloride. The information required to do that accurately is not present in the provided material, and producing an unsourced “who sells it” list would not meet a hard-evidence standard for drug patent and R&D procurement decisions.
What you can do right now without guessing
A buyer should only move forward once the supplier selection is tied to verifiable documentation for:
- GMP status (or intended use stage: R&D vs clinical vs commercial)
- Salt form confirmation (dihydrochloride)
- Analytical method and specifications aligned to the intended regulatory path
Key procurement matrix (decision-ready)
| Procurement need |
Supplier type |
Must-have proof to request |
| Clinical material |
GMP API manufacturer or GMP CMO with API capability |
GMP CoA, salt-form confirmation, full specs/impurities |
| Commercial material |
GMP API manufacturer (preferred) or integrated GMP CMO |
Batch history, validation package elements, impurity control plan |
| Lab screening only |
Distributor or non-GMP chemical supplier |
Identity (COA), basic specs, form confirmation, source disclosure where available |
| Line extension / tech transfer |
GMP CMO with salt-form control |
Development batch data, process robustness, stability under proposed conditions |
Key Takeaways
- “Mometinib dihydrochloride” supply in the market typically depends on API salt-form correctness and GMP readiness.
- Supplier categories that matter are GMP API manufacturers, GMP CMOs with API capability, and distributors only for non-GMP use.
- Without sourced evidence, a named supplier roster for mometinib dihydrochloride cannot be provided without risking incorrect company-product attribution.
FAQs
-
Is mometinib dihydrochloride commonly sold as an API or only as an intermediate?
It is typically sold as an API salt form for oncology development, but availability depends on supplier GMP scope.
-
What is the biggest risk when buying “dihydrochloride” from a catalog supplier?
Salt form and solid-state form consistency (polymorph or form drift) plus documentation sufficiency.
-
What documents distinguish a GMP API supplier from a distributor?
GMP manufacturing statements, GMP batch CoA, and a specification package tied to validated analytical methods.
-
Should buyers accept “API” if the supplier cannot confirm salt form identity?
No. Salt identity confirmation is a gating requirement for meaningful comparability and regulatory defensibility.
-
What should a buyer require for impurity and residual solvent control?
Explicit acceptance limits for related substances and residual solvents, plus analytical method details in the supplier spec/CoA package.
References
- (No cited sources available in the provided prompt.)
